Genzyme General
This article was originally published in The Gray Sheet
Executive Summary
Collaboration with a research group at The Toronto Hospital will develop cell-based therapies to treat cardiovascular disease. The partners' initial focus is on developing a treatment involving transplantation of cultured autologous cardiomyocytes into the scar tissue that replaces heart muscle after a heart attack. Clinical trials are expected to begin in the second half of 2000. Genzyme gains rights to the technology in exchange for funding all R&D and commercialization efforts